Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
7/15/26 Merck & Co (MRK) Keytruda for Uterine (Endometrial) Cancer Subscribers Only Subscribers Only Subscribers Only
7/15/26 Roche (RO) Gazyva for Membranous Nephropathy Subscribers Only Subscribers Only Subscribers Only
7/15/26 Roche (RO) Gazyva for Nephrotic Syndrome Subscribers Only Subscribers Only Subscribers Only
7/14/26 HUYA Bioscience Hiyasta for Melanoma Subscribers Only Subscribers Only Subscribers Only
7/14/26 Merck & Co (MRK) Jiatailai for Non-Small Cell Lung Cancer (NSCLC) Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/26/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
09/08/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
09/17/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update